
• Reported GAAP EPS of $0.39 down -45.83% YoY • Reported revenue of $15B up 12.43% YoY • AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.96 - $14.16 to $14.08 - $14.28, including an unfavorable $0.41 per share impact from IPR&D.
Bullish
AbbVie saw strong growth in immunology and neuroscience portfolios, advanced its pipeline with new drug approvals and positive clinical trial results, and invested in new manufacturing and R&D infrastructure.
Bearish
AbbVie experienced significant revenue declines in Humira and Imbruvica, faced an unfavorable $0.41 per share impact from IPR&D expense, and received a Complete Response Letter from the FDA for trenibotulinumtoxinE.